No annual revenue total was found in BETTERLIFE PHARMA INC.'s SEC filings.
Betterlife Pharma Inc. (BETRF) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income (TTM)
$-6.74M
-1011.4% vs year-ago TTM
Operating cash flow (TTM)
$-3.76M
-1154.9% vs year-ago TTM
Free cash flow
—
EPS
$-0.11
-10.0% vs prior year
Dividend per share
None
Shares outstanding
145.49M
+24.3% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BETRF (OTC)
- Fiscal year ends
- January 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Vancouver, British Columbia, Canada
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1464165
- Former names
- Pivot Pharmaceuticals Inc. (until Dec 3, 2019); Neurokine Pharmaceuticals Inc. (until Mar 26, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2018 Jan 31, 2018 |
FY 2017 Jan 31, 2017 |
FY 2016 Jan 31, 2016 |
FY 2016 Jan 31, 2015 |
FY 2012 Jan 31, 2013 |
|---|---|---|---|---|---|
| Operating income | -$1.0M | -$6.0M | -$10.3M | -$117,484 | — |
| Net income | -$121,182 | -$6.3M | -$10.3M | -$1.1M | $341,425 |
| Diluted EPS | — | — | -$0.11 | -$0.10 | — |
| Operating cash flow | -$395,602 | -$359,449 | -$163,942 | -$47,257 | -$31,586 |
| Total assets | $383,817 | $132,658 | $106,115 | $1,265 | $6,057 |
| Total liabilities | $429,200 | — | $435,104 | $55,790 | $680,695 |
| Stockholders' equity | -$45,383 | -$1.5M | -$328,989 | — | -$674,638 |
| Cash and investments | $64,511 | $112,421 | $71,639 | $839 | $475 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Sep 30, 2026 | Sep 29, 2026 |
| 6-K | Current report (foreign issuer) | Sep 15, 2026 | Sep 14, 2026 |
| 6-K | Current report (foreign issuer) | Sep 11, 2026 | Sep 11, 2026 |
| 6-K | Current report (foreign issuer) | Aug 24, 2026 | Aug 24, 2026 |
| 6-K | Current report (foreign issuer) | Aug 5, 2026 | Aug 3, 2026 |
| 6-K | Current report (foreign issuer) | Jun 26, 2026 | Apr 30, 2026 |
All 244 Betterlife Pharma Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.